Download full announcement

Exercise of options

EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted point-of-care business, announces that it has issued and allotted 400,000 new ordinary shares of one pence each in the share capital of the Company ("Ordinary Shares") following an exercise of options on 30 September 2020. The options had an exercise price of 27.25 pence per Ordinary Share.

Application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 400,000 new Ordinary Shares to trading on AIM will become effective on, or around, 6 October 2020 (“Admission”).

Total voting rights

Following Admission, the Company will have 454,993,227 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 454,993,227.

Enquiries:

About EKF Diagnostics Holdings plc

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.